← back to search

Jay Garg

Gene Therapy Laboratory · FR
Area of research
Rheumatology · Nephrology
Research interest
Research focused on Meteorology and Environmental science, with related work in Obinutuzumab, Reuse, Rheumatoid arthritis. Notable publications include 'Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis', 'Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis', and 'Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate'.
h-index
citations
801
works
15
NIH funding
primary concept
email

Recent publications

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
New England Journal of Medicine 2025cited by 170position: middledoi
Global Climate
Bulletin of the American Meteorological Society 2025cited by 2position: middledoi
Global Climate
Bulletin of the American Meteorological Society 2024cited by 18position: middledoi
Global Oceans
Bulletin of the American Meteorological Society 2024cited by 9position: middledoi
Global Climate
Bulletin of the American Meteorological Society 2023cited by 33position: middledoi
Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients
Transplantation Direct 2023cited by 27position: middledoi
Global Oceans
Bulletin of the American Meteorological Society 2023cited by 25position: middledoi
Global Climate
Bulletin of the American Meteorological Society 2022cited by 75position: middledoi
Global Oceans
Bulletin of the American Meteorological Society 2022cited by 17position: middledoi
Prediction of Histologic Class Using Deep Learning on Renal Biopsies from a Trial of Obinutuzumab for Proliferative Lupus Nephritis
Journal of the American Society of Nephrology 2020cited by 0position: middledoi
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
Rheumatology and Therapy 2019cited by 15position: middledoi
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
Clinical Journal of the American Society of Nephrology 2018cited by 181position: middledoi
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis
Arthritis & Rheumatology 2017cited by 90position: middledoi
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
Arthritis & Rheumatology 2016cited by 109position: middledoi
Targeting Cell Death Pathways for Therapeutic Intervention in Kidney Diseases
Seminars in Nephrology 2016cited by 30position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

· 3 papers (2016–2019)Thomas H. Schindler · Roche (Switzerland)3 papers (2020–2025)Alan Kivitz · AbbVie (United States)3 papers (2016–2019)Mark C. Genovese · Palo Alto University3 papers (2016–2019)Christine E. Codding · University of Oklahoma Health Sciences Center2 papers (2017–2019) · 2 papers (2017–2019)Xuegong Wang · Gilead Sciences (United States)2 papers (2017–2019) · 2 papers (2016–2017)Brad H. Rovin · University of Hong Kong2 papers (2018–2025) · 2 papers (2017–2019)Annie Wang · New York University2 papers (2017–2019) · 2 papers (2016–2019) · 2 papers (2020–2023) · 2 papers (2016–2019)Matthew D. Cascino · United Therapeutics (United States)2 papers (2018–2020) · 1 papers (2025–2025) · 1 papers (2025–2025)Mittermayer B. Santiago · Universidade Estadual de Campinas (UNICAMP)1 papers (2025–2025)Erica Tavares · Massachusetts General Hospital1 papers (2023–2023) · 1 papers (2023–2023)